Drivers of topoisomerase II poisoning mimic and complement cytotoxicity in AML cells

Recently approved cancer drugs remain out-of-reach to most patients due to prohibitive costs and only few produce clinically meaningful benefits. An untapped alternative is to enhance the efficacy and safety of existing cancer drugs. We hypothesized that the response to topoisomerase II poisons, a v...

Descripción completa

Detalles Bibliográficos
Autores principales: More, Piyush, Goedtel-Armbrust, Ute, Shah, Viral, Mathaes, Marianne, Kindler, Thomas, Andrade-Navarro, Miguel A., Wojnowski, Leszek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731103/
https://www.ncbi.nlm.nih.gov/pubmed/31523390
http://dx.doi.org/10.18632/oncotarget.27112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731103/
https://www.ncbi.nlm.nih.gov/pubmed/31523390
http://dx.doi.org/10.18632/oncotarget.27112

Ejemplares similares